The National Agency for Food and Drug Administration and Control (NAFDAC) has released a list of 101 products whose ...
This article was reviewed by Craig Primack, MD, FACP, FAAP, FOMA. Weight loss can be a challenge, even for those who eat healthily and exercise regularly. … ...
Novo's Clayton facility makes semaglutide, the active ingredient in Wegovy and diabetes drug Ozempic. It also does ...
Novo Nordisk has cut dozens of jobs at its Clayton, North Carolina site, part of a global restructuring as it faces slowing ...
Novo Nordisk, the Danish pharmaceutical giant behind the popular weight-loss drugs Ozempic and Wegovy, just announced plans to cut 11% of its workforce as competitors like Eli Lilly continue to ...
Centrally acting agents like phentermine/topiramate and naltrexone/bupropion aid weight reduction but lack MASLD-specific ...
Berenberg Bank just upgraded Novo Nordisk to a buy. The banker believes investor expectations have reset and it's now possible Novo Nordisk has fallen enough to bounce again. Novo Nordisk created the ...
Novo Nordisk is now deeply undervalued despite stellar fundamentals: 18% sales growth, a 29% operating profit jump, and a rock-solid balance sheet. Growth is broad-based across obesity, diabetes, and ...
Novo Nordisk has recently encountered headwinds in its core therapeutic area. The company has implemented changes that could pay off in the long run. Novo Nordisk's shares look reasonably valued. With ...
Because of its size, the drugmaker has an outsize effect on the country. Now, as it sheds jobs, forecasts for Denmark’s growth are falling, too. By Eshe Nelson The success of Novo Nordisk, the ...
Novo Nordisk is set to lay off roughly 9,000 employees across its global workforce of 78,400 as part of a newly launched restructuring initiative. In a Sept. 10 press release, the Danish ...
Two years ago, Novo Nordisk (NYSE: NVO), a Denmark-based pharmaceutical company, was performing so well that it was positively affecting the economy of its home country. However, the past 18 months ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback